ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
ABEONA THERAPEUTICS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.41−0.02 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $251.58M
- P/E (TTM)
- –
- Dividend yield
- –
ABEONA THERAPEUTICS INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | TTM Q3 18 | TTM Q2 18 | TTM Q1 18 | TTM Q4 17 | TTM Q4 13 | TTM Q3 13 | TTM Q2 13 | TTM Q1 13 | TTM Q4 12 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foundation revenues | $2.06M | $2.32M | $2.80M | $2.43M | $740.00K | $481.00K | $0 | – | – | – | – | – | 93.8% | +177.8% |
| Royalties [Member] | $135.00K | $152.00K | $202.00K | $154.00K | $200.00K | $250.00K | $235.00K | – | – | – | – | – | 6.2% | -32.5% |
| Product [Member] | – | – | – | – | – | – | – | $1.53M | $2.46M | $3.24M | $3.47M | $2.87M | – | – |
| License [Member] | – | – | $0 | $150.00K | $301.00K | $451.00K | $602.00K | – | – | – | – | – | – | – |
| Foundation Revenues [Member] | – | – | $2.80M | – | – | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Abeona Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.